Ratings Tong Ren Tang Technologies Co. Ltd. OTC Markets

Equities

TGRNF

CNE100000585

Market Closed - OTC Markets Other stock markets 08:00:02 29/12/2023 pm IST			5-day change	1st Jan Change
0.8616 ^USD	+1.47%		-.--%	-.--%

20/05	Tong Ren Tang Technologies Co. Ltd. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 09 August 2024	CI
30/04	Beijing Tong Ren Tang Gets Nod to Sell Fever Drug in Hong Kong	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
The company's attractive earnings multiples are brought to light by a P/E ratio at 10.77 for the current year.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.84 for the 2024 fiscal year.
The company's share price in relation to its net book value makes it look relatively cheap.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
TONG REN TANG TECHNOLOGIES CO. LTD.	-.--%	873M		-
DONG-E-E-JIAO CO.,LTD.	+37.29%	6.02B		B-
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-21.28%	4.19B		C+
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+4.52%	3.25B		C
TASLY PHARMACEUTICAL GROUP CO., LTD	-18.16%	2.87B		B-
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-7.70%	2.37B	-	D+
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+41.50%	1.89B		-
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-4.05%	1.58B	-	-
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-15.56%	1.54B	-	-
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-14.62%	1.5B		C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes